Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics.
Cancer Drug Resist
; 2(4): 1069-1085, 2019.
Article
em En
| MEDLINE
| ID: mdl-35582282
ABSTRACT
Delineating the contributions of specific cell signalling cascades to the development and maintenance of tumours has greatly informed our understanding of tumorigenesis and has advanced the modern era of targeted cancer therapy. It has been revealed that one of the key pathways regulating cell growth, the phosphatidylinositol 3-kinase/mechanistic target of rapamycin (PI3K/mTOR) signalling axis, is commonly dysregulated in cancer. With a specific, well-tolerated inhibitor of mTOR available, the impact of inhibiting this pathway at the level of mTOR has been tested clinically. This review highlights some of the promising results seen with mTOR inhibitors in the clinic and assesses some of the challenges that remain in predicting patient outcome following mTOR-targeted therapy.
Texto completo:
1
Bases de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Cancer Drug Resist
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Reino Unido